Intralesional Injections of Triamcinolone for Acne Vulgaris

Inclusion Criteria: * Outpatient, male or female of any race, 18 years of age or older. Female subjects of childbearing potential must have a negative urine pregnancy test at Baseline. * Diagnosed with facial acne vulgaris. * At least one (1) identifiable inflammatory lesion that, in the opinion of the investigator, is amenable to intralesional injection of triamcinolone. * Able to follow study instructions and likely to complete all required visits. * In good general health as determined by medical history at the time of screening (Investigator discretion). * Sign the IRB-approved informed consent form (including HIPAA authorization) prior to any study-related procedures being performed Exclusion Criteria: * Female subjects who are pregnant or breast-feeding. * Known hypersensitivity or previous allergic reaction to any constituent of triamcinolone injection. * Active cutaneous viral infection in any treatment area at Baseline. * Have concomitant skin disease or infection (other than acne) or presence of skin comorbidities in the areas of skin where study device will be used. * History of poor cooperation or unreliability (Investigator discretion). * Planning to move out of the area prior to study completion. * Subjects who are investigational site staff members or family members of such employees. * Exposure to any other investigational /device within 30 days prior to Visit 1.